SiBone (SIBN) Stock Price, News & Analysis

Company Overview

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Key Stats

• Today's Range: $16.61 to $17.55
• 50-Day Range: $16.39 to $19.10
• 52-Week Range: $11.70 to $20.05
• Volume: 571,245 shs
• Average Volume: 281,030 shs
• Market Capitalization: $741.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.50
• Consensus Rating: Buy

SiBone Stock Analysis - MarketRank™

SiBone scored higher than 79% of companies evaluated by MarketBeat, and ranked 195th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

SiBone has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

SiBone has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SiBone are expected to grow in the coming year, from ($0.78) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SiBone is -27.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SiBone is -27.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SiBone has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.41% of the outstanding shares of SiBone have been sold short.

Short Interest Ratio / Days to Cover

SiBone has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in SiBone has recently decreased by 4.08%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SiBone does not currently pay a dividend.

Dividend Growth

SiBone does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.3 / 5
• Environmental Score: -1.44

Percentage of Shares Shorted

4.41% of the outstanding shares of SiBone have been sold short.

Short Interest Ratio / Days to Cover

SiBone has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in SiBone has recently decreased by 4.08%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.51

News Sentiment

SiBone has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for SiBone this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, SiBone insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,866,404.00 in company stock.

Percentage Held by Insiders

Only 4.00% of the stock of SiBone is held by insiders.

Percentage Held by Institutions

98.11% of the stock of SiBone is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SIBN Stock Analysis - Frequently Asked Questions

How have SIBN shares performed this year?

SiBone's stock was trading at $14.02 at the beginning of 2025. Since then, SIBN stock has increased by 24.0% and is now trading at $17.39.

How were SiBone's earnings last quarter?

SiBone (NASDAQ:SIBN) announced its earnings results on Monday, May, 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. The business earned $47.29 million during the quarter, compared to analyst estimates of $45.13 million. SiBone had a negative trailing twelve-month return on equity of 16.00% and a negative net margin of 15.03%.
Read the conference call transcript.

Does SiBone have any subsidiaries?

SiBone subsidiaries include these companies: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.

When did SiBone IPO?

SiBone (SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are SiBone's major shareholders?

Top institutional investors of SiBone include Harbor Capital Advisors Inc. (1.35%), Peregrine Capital Management LLC (0.83%), VELA Investment Management LLC (0.30%) and Bessemer Group Inc. (0.09%). Insiders that own company stock include Laura Francis, Anthony J Recupero, Michael A Pisetsky, Anshul Maheshwari, John Gordon Freund, Timothy E Davis Jr and Mika Nishimura.
View institutional ownership trends.

How do I buy shares of SiBone?

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SiBone own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SiBone investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SIBN
• CIK: 1459839
• Web: www.si-bone.com
• Phone: (408) 207-0700
• Fax: N/A
• Employees: 350
• Year Founded: 2008

Price Target and Rating

• Average Price Target for SiBone: $22.50
• High Price Target: $25.00
• Low Price Target: $19.00
• Potential Upside/Downside: +29.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.91 million
• Net Margins: -15.03%
• Pretax Margin: -15.03%
• Return on Equity: -16.00%
• Return on Assets: -11.69%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 8.53
• Quick Ratio: 7.26

Sales & Book Value

• Annual Sales: $167.18 million
• Price / Sales: 4.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.98 per share
• Price / Book: 4.36

Miscellaneous

• Outstanding Shares: 42,620,000
• Free Float: 40,910,000
• Market Cap: $739.54 million
• Optionable: Optionable
• Beta: 0.93